Analyst Rating
based on 2 analysts
50.00%
Buy
0.00%
Hold
50.00%
Sell
Based on 2 analysts offering long term price targets for Suven Pharmaceuticals Ltd. An average target of ₹810.5
Source: S&P Global Market Intelligence
Suven Pharmaceuticals Ltd Share analysis
Suven Pharmaceuticals Ltd price forecast by 2 analysts
Downside of
High
₹1050
Target
₹810.50
Low
₹571
Suven Pharmaceuticals Ltd target price ₹810.5, a slight downside of -29.59% compared to current price of ₹1200.15. According to 2 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Suven Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:40.93%
Forecast
Actual
Including amortisation and stock based compensations
Suven Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:54.24%
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹1,140₹1,22452 Week's Low
52 Week's High
₹505.65₹1,224
| Returns % | |
| 1 Month Return | + 18.26 % |
| 3 Month Return | + 81.12 % |
| 1 Year Return | + 122.59 % |
| Market Stats | |
| Previous Close | ₹1,151.10 |
| Open | ₹1,140.00 |
| Volume | 14.05L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹29,302.97Cr |
Key Statistics
| P/E Ratio | 121.68 |
| PEG Ratio | -16.88 |
| Market Cap | ₹29,302.97 Cr |
| P/B Ratio | 8.38 |
| EPS | 11.8 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 14.31 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹29,302.97 Cr | 116.6% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹14,937.56 Cr | 25.7% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹7,286.81 Cr | 10.07% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹13,011.31 Cr | 36.92% | 0.68 | ₹218 Cr | ₹1,296 Cr | |
| BUY | ₹26,036.74 Cr | 227.1% | 0.55 | ₹179 Cr | ₹1,115 Cr |
Company Information
Share Price: ₹1200.15 per share as on 06 Sep, 2024 04:01 PM
Market Capitalisation: ₹29,302.97Cr as of today
Revenue: ₹230.69Cr as on June 2024 (Q2 24)
Net Profit: ₹60.77Cr as on June 2024 (Q2 24)
Listing date: 05 Mar, 2020
Chairperson Name: Annaswamy Vaidheesh
| Organisation | Suven Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Reports Significant Profit Decline - 11 Aug, 2024
Suven Pharmaceuticals Ltd reported a 49.6% year-on-year decline in net profit to ₹60.8 crore for Q1 ending June 30, 2024, with revenue dipping 33.6% to ₹230.7 crore.
Suven Pharmaceuticals Reports Significant Profit Decline - 09 Aug, 2024
Suven Pharmaceuticals reported a 49.6% YoY decline in net profit to ₹60.8 crore for Q1 FY25, with revenue falling 33.6% to ₹230.7 crore. Despite challenges, the company anticipates growth in the second half of FY25 and has completed the first phase of its acquisition of Sapala Organics.
Suven Pharma and Cohance Lifesciences Merger Approved - 26 Jul, 2024
Suven Pharmaceuticals has received approval from NSE and BSE for its merger with Cohance Lifesciences. The newly formed company will focus on pharma CDMO, agrochemicals CDMO, and API manufacturing. Advent holds a 50.1% stake in Suven Pharma and 100% in Cohance. Post-merger, Advent will own 66.7% of the combined entity. The management anticipates revenue and Ebitda growth for FY25, with acceleration in FY26.
Suven Pharma Receives Observation Letter for Amalgamation Scheme - 24 Jul, 2024
Suven Pharmaceuticals has received an observation letter with no adverse observations from both BSE and NSE regarding its Scheme of Amalgamation.
CCI Approves Platinum Poppy's Acquisition of Berhyanda Shares - 19 Jul, 2024
The CCI has approved the acquisition of ordinary shares of Berhyanda Limited and Berhyanda MidCo Limited by Platinum Poppy C 2024 RSC Limited, enabling it to secure an indirect non-voting economic interest in Suven Pharmaceuticals Limited.
Suven Pharma Acquires Stake in Sapala Organics, Receives Form 483 from USFDA - 15 Jul, 2024
Suven Pharmaceuticals has acquired a 51% stake in Sapala Organics and received a Form 483 with two procedural observations from the US FDA after an inspection of its subsidiary, Casper Pharma. The impact on Suven Pharma's stock remains to be seen.
Insights on Suven Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 1 Year
In the last 1 year, SUVENPHAR has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 46.75 Cr → 60.77 Cr (in ₹), with an average increase of 12.3% per quarter
- POSITIVE IMPACT
Price Rise
In the last 3 months, SUVENPHAR stock has moved up by 81.1%
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 9.54% to 9.80% in Jun 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 132.9% return, outperforming this stock by 13.4%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 50.10% of holdings in Jun 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 23.10% to 22.67% in Jun 2024 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 269.98 Cr → 248.85 Cr (in ₹), with an average decrease of 7.8% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 15.26% to 14.78% in Jun 2024 quarter
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 50.1% | 0.00 | |
| Foreign Institutions | 9.8% | 2.68 | |
| Mutual Funds | 14.78% | ||
| Retail Investors | 22.67% | ||
| Others | 2.65% | 33.19 |
Key Indicators
Suven Pharmaceuticals Ltd Valuation
Suven Pharmaceuticals Ltd in the last 5 years
Lowest (4.48x)
March 30, 2020
Industry (58.97x)
September 5, 2024
Today (121.68x)
September 5, 2024
Highest (121.68x)
September 5, 2024
Earnings and Dividends
Suven Pharmaceuticals Ltd Earnings Results
Suven Pharmaceuticals Ltd’s net profit fell -49.61% since last year same period to ₹60.77Cr in the Q1 2024-2025. On a quarterly growth basis, Suven Pharmaceuticals Ltd has generated 13.87% jump in its net profits since last 3-months.
Read More about Earnings ResultsSuven Pharmaceuticals Ltd Dividends September,2022
In the quarter ending June 2022, Suven Pharmaceuticals Ltd has declared dividend of ₹1 - translating a dividend yield of 0.96%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Suven Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Suven Pharmaceuticals Ltd shares.
Suven Pharmaceuticals Ltd (SUVENPHAR) share price today is ₹1200.15
Suven Pharmaceuticals Ltd is listed on NSE
Suven Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Suven Pharmaceuticals Ltd is ₹1224.
- Today’s lowest price of Suven Pharmaceuticals Ltd is ₹1140.
PE Ratio of Suven Pharmaceuticals Ltd is 121.68
PE ratio = Suven Pharmaceuticals Ltd Market price per share / Suven Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Suven Pharmaceuticals Ltd(SUVENPHAR) is 14.05L.
Today’s market capitalisation of Suven Pharmaceuticals Ltd(SUVENPHAR) is ₹29302.97Cr.
| Suven Pharmaceuticals Ltd(SUVENPHAR | Price |
|---|---|
52 Week High | ₹1224 |
52 Week Low | ₹505.65 |
Suven Pharmaceuticals Ltd(SUVENPHAR) share price is ₹1200.15. It is down -1.95% from its 52 Week High price of ₹1224
Suven Pharmaceuticals Ltd(SUVENPHAR) share price is ₹1200.15. It is up 137.35% from its 52 Week Low price of ₹505.65
| Suven Pharmaceuticals Ltd(SUVENPHAR | Returns |
|---|---|
1 Day Returns | 49.05% |
1 Month Returns | 18.26% |
3 Month Returns | 81.12% |
1 Year Returns | 122.59% |